Latest / Stock Movers / SK Hynix Up, Kuaishou Plunges, Sino Biopharmaceutical Up
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, podcasts, radio News.
- 0:08Speaker 2: The Stock Movers Report, your roundup of companies making moves
- 0:12Speaker 2: in the stock market, harnessing the power of Bloomberg Data.
- 0:16Speaker 3: Let's take a look at some stocks on the move
- 0:18Speaker 3: today in Asia. I'm Stephen Carol and I'm joined by
- 0:20Speaker 3: our equities reporter Winnie Sue for more. Winnie, good morning.
- 0:23Speaker 3: Let's start with sk Heinez It's buy back yesterday continuing
- 0:27Speaker 3: to repor through markets.
- 0:29Speaker 1: Yeah, exactly. That is quite a massive one. We're looking
- 0:32Speaker 1: at twenty nine billion dollars worth of a buyback that
- 0:35Speaker 1: announced yesterday evening, and that is really sending shares hired
- 0:41Speaker 1: by about eleven percent right now. And that plus how
- 0:46Speaker 1: it says that it's going to raise its shareholder return
- 0:50Speaker 1: target to more than fifty percent of its cumulative free
- 0:53Speaker 1: cash flow from twenty twenty five to twenty seven. Now
- 0:56Speaker 1: that is actually better than expected because the previous target
- 1:01Speaker 1: was just up to fifty percent versus now more than
- 1:04Speaker 1: fifty percent. So investors are really excited about those two
- 1:09Speaker 1: announcements because it's signaling to you that management is very
- 1:14Speaker 1: confident in terms of the future growth of the company
- 1:17Speaker 1: and that there is further cash returns that it's planning
- 1:21Speaker 1: for its investors. And we're seeing interestingly a very similar
- 1:25Speaker 1: move from Samsund Electronics with a report saying that the
- 1:29Speaker 1: company is planning of a shareholder return plan of about
- 1:34Speaker 1: seventy two billion dollars and that is also helping the shares.
- 1:38Speaker 1: They're up nearly ten percent as well.
- 1:41Speaker 3: Yeah, certainly really big move in those companies today. Let's
- 1:45Speaker 3: go to the Chinese instadet from Kwaishu next plunging after
- 1:48Speaker 3: their latest results. What happened exactly.
- 1:51Speaker 1: Well, that is again the latest example of the weakness
- 1:54Speaker 1: in Chinese internet names, and we are seeing shares there
- 1:58Speaker 1: down about twelve percent. One of the biggest underperformers in
- 2:03Speaker 1: Asia today now earning second quarter profitability down thirty percent
- 2:09Speaker 1: year over year as the company shifts to AI, so
- 2:12Speaker 1: highlighting how the high cost of developing AI AI centered
- 2:18Speaker 1: business is really weighing on the company's income despite seeing
- 2:22Speaker 1: a bit of a positive growth at its cling model model,
- 2:27Speaker 1: which is this AI text to video business that it
- 2:30Speaker 1: has so looking forward. It was also quite week of
- 2:34Speaker 1: a guidance for the next quarter, expecting revenue dropping year
- 2:38Speaker 1: over year for the first time ever. And we are
- 2:41Speaker 1: seeing analysts cutting the target prices on the concerns around
- 2:46Speaker 1: that weak macro environment plus the policy tightening when it
- 2:50Speaker 1: comes to e commerce space. But for sure we are
- 2:54Speaker 1: closely watching out for other Internet names and now we
- 2:57Speaker 1: have Alibaba to report later today.
- 3:01Speaker 3: And you're also watching the healthcare sector in Asia today.
- 3:03Speaker 3: This after the big moves that we saw in shares
- 3:06Speaker 3: in Maderna and Murky yesterday on news of a late
- 3:09Speaker 3: stage trial in a skin cancer vaccine.
- 3:14Speaker 1: Yeah, that is almost one of the most exciting news
- 3:17Speaker 1: I've heard recently and it is such a big moment
- 3:21Speaker 1: for science and for just cancer treatment. So this is
- 3:26Speaker 1: a personalized vaccine co developed by Moderna and Merk to
- 3:30Speaker 1: reduce the recurrence of melanoma, which is the most serious
- 3:36Speaker 1: skin disease a sink skin cancer in a large late
- 3:39Speaker 1: stage trial. And this is so such a breakthrough because
- 3:45Speaker 1: scientists have been looking for this kind of personalized cancer
- 3:48Speaker 1: vaccines for a century or so and this is the
- 3:51Speaker 1: first time we are seeing a positive late stage trial
- 3:55Speaker 1: for any mr NA based cancer therapy. And what it
- 4:00Speaker 1: does is basically they can customize the vaccines based on
- 4:04Speaker 1: the patient's specific tumor mutations, and that is such a
- 4:09Speaker 1: breakthrough that we saw Moderna shares up that one hundred
- 4:13Speaker 1: and seventy seven percent yesterday, and that's rippling into the
- 4:16Speaker 1: vaccine names and biopharma names in Asia, the likes of
- 4:20Speaker 1: Sino Biopharmaceuticals, for example, of more than ten percent, and
- 4:24Speaker 1: the healthcare sector in Asia also up by about three percent.
- 4:27Speaker 1: But the question here really is, Okay, first of all,
- 4:30Speaker 1: it has to be approved for now we are looking
- 4:33Speaker 1: at the timeline at twenty twenty seven, Plus is it
- 4:36Speaker 1: going to be applicable to other cancers as well? So
- 4:39Speaker 1: how wide of a treatment that can actually be offered
- 4:43Speaker 1: to different types of tumors? Plus the adoption rate, especially
- 4:47Speaker 1: given this whole anti vaccina movement that we are seeing
- 4:51Speaker 1: globally right now. But at least for now, it is
- 4:55Speaker 1: a very significant moment for this science.
- 5:01Speaker 2: The Stockmovers Report from Bloomberg Radio. Check back with us
- 5:05Speaker 2: throughout the day for the latest roundup of companies making
- 5:08Speaker 2: news on Wall Street and for the latest market moving headlines.
- 5:12Speaker 2: Listen to Bloomberg Radio Live, catch us on YouTube, Bloomberg
- 5:16Speaker 2: dot com, and on Applecarplay and Android Auto with the
- 5:19Speaker 2: Bloomberg Business app.